Main Article Content
Aims: Two simple and sensitive stability- indicating methods were developed and validated for the quantitative determination of sofosbuvir in presence of its degradation products.
Study Design: Ultra high performance liquid chromatography (UPLC), High performance thin layer chromatography (HPTLC) are developed for determination of sofosbuvir in presence of its degradation products, laboratory-prepared mixtures and in tablet dosage forms.
Place and Duration of Study: Analytical Chemistry Department, Faculty of Pharmacy (Girls), Al-Azhar University, between August 2018 and March 2019.
Methodology: Two simple and sensitive stability- indicating methods were developed and validated for the quantitative determination of Sofosbuvir in presence of its degradation products. The first method was an Ultra Performance Liquid Chromatography (UPLC) method, in which efficient separation was carried out on phenomenex kinetex 2.6 μm C18 100 A column using a mobile phase consisting of filtered and degassed mixture of 0.1% ortho-phosphoric acid in water and methanol with the ratio of (40:60% v/v) adjusted to pH 3.5, at a flow rate of 1 mL min-1 and UV detection at 260 nm at ambient temperature. The second method is a high performance- thin layer chromatographic one (HPTLC) in which chromatographic separation was performed on silica gel 60 F254 plates, with methanol – chloroform – ammonia (2.5: 6: 1.5 % v/v/v) as a developing system followed by densitometric determination at 261 nm. Sofosbuvir was subjected to stress conditions including alkaline, acidic and oxidative degradation.
Results: Beer’s law was obeyed over the range of 1-20 μg mL–1 for UPLC and 2-12 μg / spot for HPTC with good accuracy and precision using the two procedures, respectively. Results obtained was statistically analysed and found to be in accordance with those given by the reported method.
Conclusion: The proposed methods were successfully applied for the determination of sofosbuvir in bulk powder, laboratory prepared mixtures and pharmaceutical dosage form with good accuracy and precision. The methods were validated according to ICH guidelines. The results obtained were compared with those of the reported method and were found to be in good agreement.
Herbst DA, Reddy KR. Sofosbuvir, anucleotide polymerase inhibitor for the treatment of chronic Hepatitis C virus infection; Expert Opinion on Investigational Drugs. 2013;22: 527–536.
Abdel‐Gawad SA. Simple chromatographic and spectrophotometric determination of sofosbuvir in pure and tablet forms; European Journal of Chemistry. 2016;7(3): 375-379.
Madhav S, Prameela R. Bioanalytical method development and validation for the determination of sofosbuvir from human plasma; International Journal of Pharmacy and Pharmaceutical Sciences. 2017;9(3):35-41.
Rower JE, Jimmerson LC, Chen X, Zheng JH, Hodara A, Bushman LR, Anderson PL, Kiser JJ. Validation and application of a liquid chromatography-tandem mass spectrometry method to determine the concentrations of sofosbuvir anabolites in cells. Antimicrob Agents Chemother. 2015; 59(12):7671-9.
Shaik JO, Muniappan M, Manikanta KA, Muralidaran K, Ramulu Y, Venkat R. Estimation of sofosbuvir with validated Ultra High Performance Liquid Chromatographic (UHPLC) method in its bulk and formulations; Der Pharmacia Sinica. 2017;8(2):10-15.
Nebsen M, Eman S. Stability- indicating method and LC–MS-MS characterization of forced degradation products of sofosbuvir. Journal of Chromatographic Science. 2016;54(9): 1631–1640.
Rezk MR, Basalious EB, Karim IA. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study. Journal of Pharmaceutical and Biomedical Analysis. 2015;114:97-104.
Kalpana N, Shanmukha JV, Ramachandran D. Analytical method development and validation for the simultaneous estimation of sofosbuvir and velpatasvir drug product by reverse phase high performance liquid chromatography. Asian Journal of Pharmaceutical and Clinical Research. 2018;11(2):164-168.
Benzil D, Ramachandraiah C, Devanna N. Analytical method development and validation for the simultaneous estimation of sofosbuvir and daclatasvir drug product by RP-HPLC method. Indo American Journal of Pharmaceutical Research. 2017;7(07): 480-487.
Chenwei P, Yongping C, Weilai C, Guangyao Z. Simultaneous determination of ledipasvir, sofosbuvir and its metabolite in rat plasma by UPLC–MS/MS and its application to a pharmacokinetic study. Journal of Chromatogr B Analyt Technol Biomed Life Scince. 2016;1008:255-9.
Ariaudo A, Favata F, De Nicolò A, Simiele M, Paglietti L, Boglione L, Cardellino CS, Carcieri C, Di Perri G, Avolio A. A UHPLC–MS/MS method for the quantification of direct antiviral agents simeprevir, daclatasvir, ledipasvir, sofosbuvir/GS-331007, dasabuvir, ombitasvir and paritaprevir, together with ritonavir, together in human plasma. Journal of Pharmaceutical and Biomedical Analysis. 2016;5(125): 369-375.
Nemade RM, Dole MN, Sawant SD. Development and validation of stability indicating RP-HPLC method for the estimation of sofosbuvir by forced degradation studies. World Journal of Pharmacy and Pharmaceutical Sciences. 2017;6(4):1503-1512.
Lalitha KV, Raveendra RJ, Devanna N. Stability indicating RP-HPLC method development and validation for estimation of sofosbuvir in pharmaceutical dosage form; The Pharma Inonvation International Journal. 2018;7(5): 656-662.
Mukthinuthalapati M, Gunnam R, Sunkara C. New stability indicating ultrafast liquid chromatographic method for the determination of sofosbuvir in tablets. Asian Journal of Pharmaceutics. 2018;12(1): 151-157.
ICH Q2 (R1). Validation of analytical procedures: Text and methodology. Geneva; 2005.
Mendham J, Denney RC, Barnes JD, Thomas MJ. Vogel's; Textbook of Quantitative Chemical Analysis, 6th Ed. London England; 2008.